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 47 
ABSTRACT 48 
 49 
CONTEXT: Care home residents are at risk of malnutrition through reduced overall food intake, 50 
‘anabolic resistance’ in ageing muscle and high prevalence of medical morbidity and functional 51 
dependency. There has been limited consensus regarding effectiveness of a high protein diet on 52 
quality of life or clinical outcomes for care home residents. 53 
 54 
OBJECTIVE: To evaluate the effectiveness of non-meat, high protein supplementation on Health-55 
Related Quality of Life (HRQOL) and relevant clinical and nutritional outcomes in older people in the 56 
care home setting.  57 
 58 
DATA SOURCES: We searched EMBASE, AMED, CINAHL, MEDLINE, and the Cochrane Registry of 59 
Clinical Trials, OpenGrey, clinicaltrials.gov, the WHO clinical trial registry and the ISRCTN and NIHR trial 60 
portfolio (to February 2018) for randomised controlled trials.  61 
 62 
DATA EXTRACTION: We extracted data from included trials if they assessed people aged 65 years and 63 
over living in care homes, who received a protein supplementation compared to not.  64 
 65 
DATA ANALYSIS: We assessed trial quality using Cochrane Risk of Bias tool and meta-analysis was 66 
undertaken when appropriate.  67 
 68 
RESULTS: 17 papers with 1,246 participants fulfilled the inclusion criteria. All studies were low or 69 
moderate quality. No evidence of improving HRQOL when the SF-36 was used (Standardised Mean 70 
Difference (SMD: -0.10; 95% CI: -0.51 to 0.31; p=0.62), although significant improvement was seen in 71 
the single trial using EQ-5D (SMD: 2.58; 95% CI: 2.05 to 3.10; p<0.00001).    72 
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 73 
CONCLUSIONS: Non-meat, high-protein oral supplements can improve markers of nutritional status in 74 
care home residents. However, there is insufficient high-quality evidence to determine the effect of 75 
such interventions for older adults in care homes with regard to HRQOL.   76 
 77 
SYSTEMATIC REVIEW REGISTRATION:  PROSPERO - Reg No: CRD42015029313. 78 
 79 
KEYWORDS: High protein; care homes; older people; quality of life; appetite 80 
81 
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 82 
INTRODUCTION 83 
 84 
In the UK 425,000 individuals live in care homes for older people.  These are long-term care 85 
facilities which may, or may not, have specialist nursing input but which universally provide 86 
care for people with multiple morbidities and advanced functional dependency and who can 87 
no longer be supported in their own home. 1  The care home bed-base is about three times 88 
that for acute hospitals and care outcomes for care home residents are increasingly 89 
recognised to impact upon all of health and social care.2  An important source of morbidity for 90 
care home residents is malnutrition, defined as a state of nutrition in which a deficiency, 91 
excess or imbalance of energy, protein and other nutrients causes measurable adverse effects 92 
on tissue/body form, function and clinical outcome.3  This affects approximately 30% of older 93 
people living in care homes with a particular risk of protein energy malnutrition.4  The 94 
multitude of poor outcomes attributable to inadequate nutrition include: increased risk of 95 
infections, dehydration, falls, inability to perform activities of daily living (ADLs) and reduced 96 
health-related quality of life (HRQOL).5  While malnutrition does not have to be an 97 
inevitability of ageing, there are several factors putting older adults at risk, including reduced 98 
appetite, poor dentition, swallowing problems, altered taste and smell.5  All of these may be 99 
addressed by high protein oral nutritional supplements (ONS), which may be of particular use 100 
in care homes because the care home staff supervise both dietary intake and administration 101 
of medicines/supplements.6,7 102 
 103 
The most commonly administered ONS are protein enriched drinks which are easy to 104 
administer, require no mastication and are less satiating than solids.8  Supplementation of 105 
dietary protein from a non-meat source avoids matters of cultural beliefs around food 106 
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choices, as several religions and cultures prohibit consumption of particular meats, and this 107 
can be more sustainable from an environmental perspective.9,10 While animal sources of 108 
protein deliver all the essential amino acids, the environmental impact from producing 109 
livestock for meat is almost double that associated with supporting a lacto-ovo-vegetarian 110 
diet.11  111 
 112 
While many older people are affected by multiple chronic diseases, most regard the presence 113 
or absence of disease less important than their overall quality of life.12  Numerous systematic 114 
reviews have reported the prevalence of malnutrition among older adults.  However, there is 115 
little evidence from systematic reviews to establish the best nutritional support for older 116 
adults in care homes.13  Older adults are at particular risk of protein energy malnutrition as a 117 
result of reduced overall food intake and ‘anabolic resistance’ in ageing muscle.6,14 118 
Additionally, few papers have assessed the evidence regarding effectiveness of a high protein 119 
diet on quality of life or clinical outcomes for care home residents.15,16  The primary purpose 120 
of this study was to address this and to perform a systematic review to assess the effect of 121 
supplementation on quality of life for older people living in care homes.  122 
 123 
 124 
 125 
METHODS 126 
 127 
Protocol 128 
The protocol for the review was registered on PROSPERO (Reg No: CRD42015029313). 129 
 130 
Reporting 131 
This systematic review has been reported in accordance with the PRISMA guidelines (Table 132 
S1).17 133 
  134 
 135 
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 Search Strategy 136 
A primary literature search was performed using the published literature databases: EMBASE, 137 
AMED, CINAHL, MEDLINE, and the Cochrane Registry of Clinical Trials. In addition, 138 
unpublished literature databases were also searched including OpenGrey, clinicaltrials.gov, 139 
the WHO clinical trial registry and the ISRCTN and NIHR trial portfolio.  We searched 140 
databases from their inception to 1st February 2018. The MEDLINE search strategy is 141 
presented in Table S2 and was modified for each database. We reviewed the reference lists of 142 
eligible studies and contacted the corresponding authors from each included paper where 143 
contact details were available, to identify any previously omitted trials. Three replies were 144 
received out of 13 enquiries. 145 
 146 
Eligibility 147 
We included studies which were: randomised controlled trials involving a non-meat, high-148 
protein dietary intervention; for people who were aged 65 years or over; and conducted on 149 
residents in care homes. We defined high protein supplements as including >20g of protein 150 
and >20% total calorie value from protein. We also included moderate protein supplements if 151 
containing >10g protein or >10% of total calorie value from protein. We excluded trials where 152 
participants were recruited during acute hospital or rehabilitation unit admissions or 153 
conducted in sheltered housing settings. We included papers irrespective of country of origin, 154 
or language or age of publication. We included all comparison arms which may have been 155 
controls assigned to a standard diet or a placebo product, however we excluded trials where 156 
there were co-interventions combined with a dietary intervention e.g. dietary intervention 157 
plus physical activity.  Where trials presented data on multiple intervention arms e.g. dietary 158 
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intervention vs. dietary intervention and physical activity vs. physical activity alone, data from 159 
the dietary intervention alone group were extracted.  160 
 161 
Study Identification 162 
Two reviewers (AICD, SA) independently screened all titles and abstracts against the above 163 
pre-defined eligibility criteria. We obtained the full-text of each paper which met the eligibility 164 
criteria and these were re-reviewed independently by the two reviewers (AICD, SA). We 165 
included those which met the criteria in the final analysis. Where disagreements occurred for 166 
paper eligibility, these were discussed between the two reviewers and adjudicated by two 167 
senior reviewers (TOS, PKM).  168 
 169 
Outcomes and Data Extraction 170 
The primary outcome was health related quality of life (HRQOL), including Short Form-36 (SF-171 
36), EQ-5D, and Dementia Quality of Life Measure (DEMQoL). Secondary outcomes included: 172 
adverse events (including admissions to hospital, gastrointestinal symptoms), falls, functional 173 
assessments, body weight, body mass index (BMI), mid-upper arm circumference (MUAC) and 174 
grip strength. Data were extracted by one reviewer (AICD) and verified by a second reviewer 175 
(SA). Disagreement was resolved by discussion and review of the source paper and 176 
adjudicated by one senior reviewer (TOS). Data extracted included: participant characteristics, 177 
details of the dietary intervention, trial design features and the outcomes of interest.   178 
 179 
For body weight, BMI and MUAC, we recorded the change in each value for each group, and 180 
where this value was not presented in the data, an estimate was made using the difference in 181 
 
 
8 
 
mean values for these outcomes from before and after intervention with an estimated 182 
standard deviation (SD) using a correlation coefficient of 0.5.18 183 
 184 
Quality Assessment 185 
We assessed the quality of all included studies using the Cochrane Risk of Bias tool.19  This 186 
was performed independently by two reviewers (AICD, SA). Any disagreement in appraisal 187 
score was satisfied through discussion and adjudicated by a third reviewer (TOS).  188 
 189 
Data Analysis 190 
All the studies were RCTs. Effect size of such trials depends on how the ‘control’ has been 191 
defined.  Study heterogeneity was assessed through examination of the data extraction table, 192 
assessing between-study variability in respect to participant, recruitment, intervention and 193 
any co-interventions. We conducted a narrative analysis (reporting the trends in results 194 
(descriptive and statistical) rather than pooling the data into a meta-analysis) when there was 195 
study heterogeneity or insufficient data (less than two dataset presenting mean and standard 196 
deviation or event count data for a specific outcome) to pool results. We performed a meta-197 
analysis when there was low risk of study heterogeneity. We assessed statistical 198 
heterogeneity using the inconsistency-value (I2) and Chi2. Where I2 was 30% or less and Chi2 199 
p>0.10, we conducted a fixed-effects model analysis. When these were not met, we 200 
performed a random-effects model. We evaluated all continuous outcomes of HRQOL, 201 
functional assessment, body weight, BMI, MUAC and grip strength using mean difference 202 
(MD) for individual papers and presented in forest plot or standardised mean difference 203 
(SMD) when trials used different measurements to capture the same domain. We assessed  204 
categorical outcomes such as adverse events and falls using a risk ratio (RR).  205 
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 206 
We presented all analyses with 95% confidence intervals (CI) and forest-plots. We performed 207 
pre-defined sub-group analyses of study outcomes by duration of intervention (> or ≤ 12 208 
weeks) and total protein content. We classified protein content as high (>20g protein), 209 
moderate (10-20g protein) or low (<10g protein). We classified calorie content as high (>20% 210 
calories from protein), moderate (10-20% calories from protein), or low (<10% calories from 211 
protein). Follow-up intervals were up to two years post-randomisation. We planned to 212 
present a funnel plot for the primary outcome analysed and/or any analysis where there was 213 
a minimum of 10 datasets, to assess small sample size publication bias.19  We intended to 214 
examine the clustering effect if the original papers reported the data accounted for clustering 215 
within a care home.  We conducted all analyses in collaboration for verification by two 216 
reviewers (AICD, TOS) using Review Manager (RevMan).20  For all analyses, a P≤0.05 was 217 
deemed statistically significant.  218 
 219 
We made an analysis of the weight of the evidence for each individual outcome using the 220 
GRADE approach.21,22  Through this, we categorised the strength of evidence underpinning 221 
each analysis as high, moderate, low or very low, with evidence graded based on study 222 
design, study quality, consistency, directness of evidence, precision and reporting bias.21,22 223 
 224 
RESULTS 225 
 226 
Study Selection 227 
The results of the search strategy are illustrated in the PRISMA flow-chart (Figure S1). As this 228 
illustrates, the searches identified 431 potentially relevant papers, of which 17 fulfilled the 229 
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inclusion criteria.6,23-38 Two of the included papers reported on the same trial but participants 230 
were only counted once.26,35 On stratifying the trials by protein content of the intervention, 231 
five fulfilled our criteria of high protein (>20g protein and >20% of total calories from 232 
protein)6,26,27,33,35,37 and 12 fulfilled our criteria of moderate protein (>10g protein or >10% 233 
calories from protein).23-25,28-32,34,36,38 234 
 235 
Study Characteristics 236 
Study characteristics are summarised in Table 1.  A total of 1246 participants were identified 237 
from 16 trials, (range: 34 to 175 participants).23,32 This included 271 males and 934 females; 238 
the gender of 41 participants was not documented in one trial.29 The study mean ages ranged 239 
from 78.7 to 89.6 years.30,34 The presence of dementia or cognitive impairment indicated by 240 
Mini Mental State Examination (MMSE) score was described in 13 trials.23-32,35,36,38 In this 241 
systematic review, MMSE score of nine or below indicated severe cognitive impairment, 10 to 242 
18 moderate cognitive impairment, 19 to 23 mild cognitive impairment and 24 to 30 as 243 
normal cognition.39 In the included trials, mean baseline MMSE ranged from 18 to 2623,29 and 244 
in three trials 100% of participants had a diagnosis of dementia.30-32 There was no consistent 245 
measure of frailty, but several trials provided information on the prevalence of chronic 246 
illness,25,28,32,34,35,37,38 ranging from a mean of 1.8 to five comorbid diseases.25,28   247 
 248 
The standard diet for participants prior to intervention contained a mean of 1560 kcal and 249 
56g of protein daily. Interventions were mainly liquid: 10 studies used a milk based 250 
supplement,6,24-27,30,31,35-38 one used a soya drink,28 three used an enriched diet or a choice of 251 
supplement,32-34 one used high protein cookies,23 and one used an amino acid supplement29.  252 
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Intervention protein content ranging from 8g29  to 40g33 with total calories 32kcal29 to 253 
600kcal.26,33-3621,28-31 The duration of intervention ranged from four weeks6 to nine months.37 254 
The comparison used in 10 trials was standard diet,6,23,24,26,27,30-33,35,36 while four trials used a 255 
placebo non-calorie drink,25,30,37,38 one trial used a snack of unspecified content,28 one trial 256 
used a placebo maltodextrin tablet,29 and one provided dietary advice.34  257 
 258 
 259 
 260 
Risk of Bias 261 
 262 
A summary of the Risk of Bias quality assessment is presented in Figure S2 and GRADE 263 
assessment of outcomes in Table 2. There was a strong risk of selection and performance bias 264 
due to the lack of blinding of participants and/or personnel in 14 trials,6,23,25-28,30,31,33-38 and 265 
unclear blinding in two further trials.24,30  A placebo supplement was employed in six 266 
trials,25,28-30,37,38 and blinding of the outcome assessor was described in five trials.25,29,36-38  The 267 
risk of reporting bias was largely unclear6,23-37 and risk of attrition bias was high with an 268 
attrition rate >15% in seven trials30,33-38 and not described in three.6,23,24 269 
 270 
Health Related Quality of Life 271 
 272 
HRQOL was assessed by SF-36 in two trials29,33 and the EQ-5D in one trial.34 Heterogeneity 273 
was too high to draw conclusions from meta-analysis of the three trials, although this can be 274 
seen in Figure 1 for interest only.  On subgroup analysis, there was no evidence of improving 275 
HRQOL when the multi-dimensional assessment tool SF-36 was used (SMD: -0.10; 95% CI: -276 
0.51 to 0.31; p=0.62; 2 trials), although significant improvement was seen in the single trial 277 
using EQ-5D for which the intervention was classed as moderate protein content (SMD: 2.58; 278 
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95% CI: 2.05 to 3.10; p<0.00001; 1 trial).  Due to the significant heterogeneity between the 279 
trials (I2 = 96%) and based on the GRADE assessment, the evidence was graded low quality.  280 
 281 
Adverse events, deaths and falls 282 
Four trials reported data on death25,34,35,38 and eight reported data on adverse events.24-283 
27,30,36,38 There was no significant difference in the number of reported adverse events (RR: 284 
1.11; 95% CI: 0.70 to 1.76; Figure 2) and deaths (RR: 0.53; 95% CI: 0.22 to 1.25; Figure S3).  285 
There was no available data on the incidence of falls in any of the trials.  Study heterogeneity 286 
was not significant for analysis of adverse events (I2 = 20%) or deaths (I2 = 0%). Based on the 287 
GRADE assessment, the evidence underpinning the assessment of adverse events, deaths and 288 
falls was graded low quality. 289 
 290 
Functional Assessment 291 
Two trials reported data on functional outcomes using the Barthel Index33,35 and two assessed 292 
this domain using an alternative ADL based score.24,30 Study heterogeneity was not significant 293 
(I2 = 0%). There were no significant differences between the control and intervention groups 294 
(SMD: -0.04; 95% CI: -0.29 to 0.22; p=0.57; Figure S4) including when limiting to the high 295 
protein studies 33,35 (SMD: -0.11; 95% CI: -0.44 to 0.23; p=0.41).  Based on the GRADE 296 
assessment, the evidence was graded low quality. 297 
 298 
Body Weight 299 
The mean change in mean body weight was reported in 13 trials.23-28,30,31,33-36,38  Meta-analysis 300 
showed significant increase in mean body weight with intervention across all included trials 301 
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(MD: 1.11; 95% CI: 0.97 to 1.24; p<0.0001; Figure S5). This effect was also evident in the high 302 
protein group 26,27,33 (MD: 2.12; 95% CI: 1.34 to 2.91; p<0.00001; Figure S5), and by a smaller 303 
magnitude in the moderate protein group (MD: 1.08; 95% CI: 0.94 to 1.21; p<0.00001; Figure 304 
S5).23-25,28,30,31,34-36,38 Based on the GRADE assessment, the evidence was graded moderate 305 
quality with overall substantial study heterogeneity (I2 = 75%). 306 
  307 
Body Mass Index 308 
The mean change in BMI was reported in eight trials.24,27,28,30,33,35-37 Meta-analysis showed 309 
significant increase in mean BMI across all included trials (MD: 0.86; 95% CI: 0.61 to 1.10; 310 
p<0.00001; Figure S6). This effect was seen in both the high protein group 27,33,37 (MD: 1.05; 311 
95% CI: 0.68 to 1.41; p=0.0004; Figure S6) and in the moderate protein group 24,28,30,35,36(MD: 312 
0.70; 95% CI: 0.37 to 1.03; p<0.00001; Figure S6).  The analyses on BMI were graded as 313 
moderate quality evidence using the GRADE approach with low overall study heterogeneity (I2 314 
= 0%). 315 
 316 
Mid-upper-arm Circumference (MUAC) 317 
The mean change in MUAC was reported in six trials.24,26,28,30,35,36 The MUAC was maintained 318 
better in the intervention group than the control group (MD: 0.51; 95% CI: 0.23 to 0.79; 319 
p=0.0004; Figure S7).  The GRADE assessment for change in MUAC measures was moderate 320 
quality with substantial overall study heterogeneity (I2 = 73%).  321 
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 322 
Grip Strength 323 
Grip strength was assessed in five trials. 24,27,32,33,35 These demonstrated substantial statistical 324 
heterogeneity (I2 = 60%).  There was a significant change in grip strength in the ‘moderate’ 325 
protein subgroup (MD: 1.29; 95% CI: 0.45 to 2.14; p= 0.003; Figure S8), and although the 326 
change in the ‘high protein’ subgroup was not statistically significant, there does appear to be 327 
a tendency of an effect (MD: 0.63; 95% CI: -0.05 to 1.32; p=0.07; Figure S8). Based on the 328 
GRADE assessment, the evidence was graded low quality. 329 
 330 
Duration of Interventions 331 
There were 12 trials (reported in 13 papers) with ≤12 week intervention duration6,23-27,29-35  332 
and four trials with intervention lasting >12 weeks.28,36-38  Minimum length of intervention 333 
was four weeks6 and longest duration of intervention was nine months.37 Subgroup analysis 334 
by duration of intervention (> or ≤ 12 weeks) was not significant for adverse events (p=0.84), 335 
deaths (p=0.61), change in body weight (p=0.12) or change in BMI (p=0.16). However, there 336 
were significant subgroup differences for MUAC (p=0.005) with stronger effect for > 12 weeks 337 
of intervention (MD 0.95; 95% CI: 0.53 to 1.37; p<0.00001) compared to ≤ 12 weeks (MD 338 
0.14; 95% CI: -0.24 to 0.52; p=0.47). There was insufficient data to examine the effect of 339 
duration of intervention for grip strength.  340 
 341 
DISCUSSION 342 
 343 
The key finding of our systematic review is that whilst a non-meat, high protein enriched 344 
dietary intervention appears to be effective for surrogate markers of clinical outcomes, there 345 
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is a paucity of high-quality evidence of the affect regarding HRQOL, an important health 346 
outcome in old age.  347 
 348 
Surprisingly, few trials objectively measured HRQOL. It was interesting to note that even 349 
within the high protein subgroups, there was no evidence of improving HRQOL on a 350 
multidimensional SF-36 assessment (p=0.62).  Nonetheless the single trial which reported EQ-351 
5D demonstrated a significant improvement in HRQOL even at the moderate protein criteria 352 
(p<0.00001).34  Since this was only a single study which presented with a number of 353 
methodological limitations, the evidence for EQ-5D remains limited, but does provide a signal 354 
which should be further investigated.  Notably, of those studies including HRQOL as an 355 
outcome measure, inclusion of participants with a diagnosis of dementia was lacking.  This 356 
absence of data on the effect of high protein diet on HRQOL in care homes for those with 357 
cognitive impairment or dementia must be addressed in future research given that this group 358 
comprises a significant proportion of care home residents. Perhaps this paucity of data 359 
reflects the difficulties in assessing self-reported measures like HRQOL in populations with a 360 
high prevalence of dementia using validated tools without relying on a proxy.  Even in 361 
relatively simple HRQOL measures with validated proxy versions, most notably, the EQ-5D, 362 
there are acknowledged issues with relying on proxy respondents in the care home setting.40  363 
However, dementia-specific HRQOL measures, such as the DEMQoL, should be considered for 364 
future studies.41   365 
 366 
Only four trials incorporated an objective measure of change in function 24,29,33,35 (Barthel 367 
Index or ADL score) and it is possible that the time frame of the included trials was too short 368 
to show any significant variation. Similarly, whilst there was a tendency for a difference, the 369 
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study interventions did not significantly differ by grip strength (p=0.07). However grip 370 
strength measures have previously been noted to be very low among care home residents42 371 
and may be affected by both a floor effect and poor sensitivity to change.  It could be that the 372 
relatively invasive nature of the investigations to measure such outcomes, such as muscle 373 
biopsy and DEXA scanning, in cohorts of older, frailer individuals has proved off-putting for 374 
researchers working in the care home setting. More recent innovations in measuring muscle 375 
turnover, including microbiopsy, ultrasonographic and excreted amino-acid derived indices of 376 
muscle turnover could potentially allow more sensitive outcome measures to be employed in 377 
this very frail cohort.43   378 
 379 
While no significant change in adverse effects or deaths were noted among participants 380 
receiving a protein-rich nutritional intervention, a previous meta-analysis of protein and 381 
energy supplementation in older people reported that there was a reduction in the mortality 382 
rate for those malnourished at baseline.15,44  In the trials included in this review, generally 383 
only those in the ‘normal’ BMI range were randomised, and therefore changes may have 384 
been apparent if the low BMI, and therefore likely more malnourished group were also 385 
included.   386 
 387 
It is important to consider that the population represented in the studies may have been a 388 
sub-cohort of the care home population, rather than representative of the population as a 389 
whole.  Certainly the reported co-morbidities in those trials which described this, were 390 
significantly lower than in most cohort studies of care home residents, suggesting that this 391 
may have been a less comorbid and less frail sub-population.  Of note, those studies which 392 
were conducted in groups without dementia were almost certainly a subset, given that the 393 
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estimated prevalence of dementia in cohort studies of care home residents is between 69% 394 
and 80%. 45,46 395 
 396 
Meta-analysis found small but statistically significant gains in both body weight (MD: 1.11kg) 397 
and BMI (MD: 0.86 kg/m2), with a more significant effect noted in the higher protein group on 398 
sub-analysis (MD: 2.12kg).  Likewise, other meta-analyses also found significant increases in 399 
body weight following protein supplementation in older adults.44,47  However, we recognise 400 
an increase in skeletal muscle mass specifically, rather than body weight, would be the 401 
desired outcome for improved function and HRQOL.  While a meta-analysis by Dewansingh et 402 
al showed  a tendency to increase lean body mass from supplementing with >20g of protein 403 
per day, a trial of long-term leucine supplementation in healthy older men did not improve 404 
skeletal muscle mass or strength.47,48  Lean body mass is an important surrogate marker of 405 
nutritional status, which should be included in future studies, this was omitted from this 406 
meta-analysis as there were no results available for any of the studies.    407 
 408 
It has been previously suggested that nutritional status can be improved by protein 409 
supplementation.44,49,5011,38,39 Our review supports that the macronutrient composition of 410 
nutritional supplements, in terms of the protein content, may have a direct influence on the 411 
extent of nutritional gains derived by older adults in residential care. Similarly, a study of 412 
protein intake for more than 2,000 elderly participants demonstrated that those in the 413 
highest quintile of protein intake lost significantly less lean body mass over three years than 414 
those in the lowest quintile.51 This is particularly interesting given that protein rich diets have 415 
gained huge popularity as a weight loss strategy, in part relying on the satiating effect of 416 
protein to prevent excess calorie ingestion.52   417 
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 418 
The strengths of this study relate to the systematic way in which we have approached the 419 
literature.  The main limitations relate to the narrow focus of our question, with focus on non-420 
meat protein supplementation and HRQoL related outcomes in a care home setting.  The 421 
paucity of data in this arena, whilst an important catalyst to further research, should not be 422 
seen as representative of the broader literature on nutrition and patient outcomes. 423 
 424 
 425 
CONCLUSION 426 
High-protein oral supplements can improve markers of nutritional status (body weight and 427 
BMI) in care home residents, but there is insufficient high-quality evidence to determine the 428 
effect of non-meat, high protein interventions for older adults in residential care with regard 429 
to HRQOL.  430 
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Figure 1: Forest plot to assess quality of life assessments between the interventions on meta-634 
analysis 635 
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Figure 2: Forest plot to assess the adverse events reported between the interventions on 641 
meta-analysis 642 
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Table 1: Summary of the characteristics of the included studies  
Study Country/ 
Setting 
Number  
(control/ 
intervention) 
Mean Age  Percentage 
female  
(%) 
Baseline cognition Mean baseline BMI Baseline Diet Dietary Intervention Intervention 
protein 
content  
(g) 
Intervention 
energy 
content  
(Kcal) 
Placebo Duration of 
intervention 
and follow-up 
Smoliner et 
al 33 
 
Germany/ 
 
Nursing homes 
52  
(30/22) 
85.2  
 
73% Not specified CG: 22.5+-3.4 
IG: 21.6+-3.6 
2000kcal 
80g protein 
Enriched diet (using 
cream/oil) plus 300ml 
snacks 
40  
(from snacks 
alone) 
600 
(from snacks 
alone) 
No 12 weeks 
Bonnefoy 
et al 37 
France / 
Retirement 
home 
 
57  
(27/30) 
83.0 88% 0% dementia 
(excluded) 
CG: 27.32+-0.8 
IG: 27.13+-0.9 
2000kcal 
 
400ml supplement 
drink 
30 400 400ml non-
calorie/ 
protein drink 
9 months 
Iuliano et al 
6 
Australia/ 
Low level care 
home 
130  
(62/68) 
86.5 78% Not specified CG: 25.4+-4.9 
IG: 23.7+-5.0 
1497+-307kcal 
56+-15g protein 
2 servings of dairy 
foods (liquid/solid) 
25+-12 215+-299 No 4 weeks 
Josbe et al 
26; Stange 
et al 35 
Germany/ 
Nursing homes 
87  
(42/45) 
87.0 91% CG: 66% dementia 
IG: 80% dementia 
CG: 22.5+-3.1 
IG: 23.0+-3.4 
1263+-374 kcal 
41.3+-15.1g 
protein 
250ml Fortimel 
Compact 
24  
(note one 
study reported 
as 48 but same 
intervention) 
600 No 12 weeks 
Lauque et 
al 27 
France/ Nursing 
homes 
 
35 in 
comparable 
groups of 
same BMI 
status  
(22/13) 
85.4 
(estimated) 
84% CG: 68% dementia 
IG: 86% dementia 
CG: 21.8+-0.9 
IG: 22.3+-0.7 
1573kcal 
60g protein 
300-400ml nutritional 
supplement drink 
24 393+-23 No 60 days 
Stow et al 36 UK/ 
Care and 
nursing homes 
 
93  
(32/32+29) 
Not described 82% CG: 78% dementia 
 
IG(A): 78% dementia 
 
IG(B): 69% dementia 
CG: 19 (17-20.5) 
 
IG(A): 20.1 (18.7-24.8) 
 
IG(B): 18.4 (17.6-21.6) 
1553kcal 
41g protein 
A) 250-400ml food 
based liquid 
supplement 
 
B) 250-400ml liquid 
nutritional 
supplement 
A) 20-25 
 
 
 
B) 24 
A) 600 
 
 
 
B) 600 
No 6 months 
Kwok et al 
24 
Hong Kong/ 
Nursing home 
 
51  
(24/28) 
CG: 79.7 
IG: 81.2 
60%  CG: 9% dementia 
IG: 32% dementia 
CG: 20.1+-3.1 
IG: 19.1+-3.1 
1198+-403kcal 
61.6+-21.2g 
protein 
2 cups of low-lactose 
milk 
18.8 175 No 7 weeks 
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Parsons et 
al 34 
UK/ 
Care home 
 
104  
(51/53) 
CG: 87.3 
IG: 89.6 
86% 0% dementia 
(excluded) 
39% BMI <18.5 
41% BMI 18.5-20 
1360kcal 
51.8g protein 
Voluntary intake of 
range of supplements 
Target 16 Target 600 Dietary 
advice 
12 weeks 
Fiatarone 
et al 25 
USA/ 
Care home 
 
50  
(26/24) 
CG: 89.2 
IG: 85.7 
62%  
 
Mean MMSE 
CG: 22.2+-1 
IG: 22.7+-1.3 
CG: 25.8+-0.5 
IG: 25.4+-0.7 
1485+-58kcal 
 
240ml Supplement 
drink 
15.3 360 240ml no 
calorie 
/protein 
drink 
10 weeks 
Pouyssegur 
et al 23  
France/ Nursing 
home 
 
175  
(87/88) 
CG: 86.8 
IG: 85.4 
80% Mean MMSE 18+-8.3 19.2+-2.9 Not specified 8 high protein cookies 11.5 244 No 6 weeks with 
18 weeks 
follow-up 
Young et al 
32 
Canada/ 
Care home 
 
34  
(34/34) 
Crossover 
study 
88.2 79% 100% dementia 23.8+-3.6 1514kcal 
54.7+-17.4g 
protein 
Various – mainly 75% 
of a supplement bar 
and a glass of juice 
10.6 250 No 12 weeks 
Wouters-
Wess et al 
30 
The 
Netherlands/ 
Psychogeriatric 
nursing home 
 
34  
(16/18) 
82.7 85% 100% dementia 24.5+-4.2 1543+-377kcal 
53.7+-18.3g 
protein 
200ml supplement 
drink 
11.2 300 No 5 weeks 
Lee et al 28 Taiwan/ 
Nursing home 
 
92 
(45/47) 
CG: 80.2 
IG: 78.9 
58% Mean MMSE 
CG: 14.1+-6.1 
IG: 15.0+-5.5  
CG: 20.31+-2.61 
IG: 20.43+-2.50 
Not specified 50g soy-protein based 
drink 
9.5 250 Afternoon 
snack 
(content not 
specified) 
24 weeks 
Wouter-
Wess et al 
31 
The 
Netherlands/ 
Psychogeriatric 
nursing home 
35  
(16/19) 
CG: 78.7 
IG: 85.3 
89% 100% dementia CG: 20.7+-2.7 
IG: 20.7+-3.2 
1496+-415kcal 
55+-16g 
250ml supplement 
drink 
8.5 273 250ml non-
calorie, no 
protein drink 
3 months 
Manders et 
al 38 
The 
Netherlands/ 
Care and 
nursing homes 
 
176  
(57/119) 
CG: 81.0 
IG: 81.0 
74%  Mean MMSE 
CG: 24.0 (11.2-27.8) 
IG: 23.0 (9.6-27.4) 
CG: 25.0+-3.5 
IG: 26.1+-3.7 
1793+-332kcal 
58.8+-15.4g 
protein 
250ml nutrient drink 8.75 250 250ml non-
calorie, no 
protein drink 
24 weeks 
Rondanelli 
et al 29 
Italy/ 
Nursing home 
 
41  
(21/20) 
CG: 79.9 
IG: 83.5 
Not 
specified 
Mean MMSE 
CG: 21.1+-2.04 
IG: 26.05+-2.09 
CG: 22.1+-2.6 
IG: 21.8+-2.3 
59+-8g protein 8g Essential amino 
acid supplement 
8 32 Maltodextrin 
tablet 
8 weeks 
Abbreviations: CG (control group); IG (intervention group); MMSE (mini mental state exam); BMI (Body mass index)
 
 
33 
 
 
Table 2: GRADE Assessment of Outcomes 
 
Outcome Measure 
Quality Assessment Number of Participants Effect  
EVIDENCE 
GRADE 
Design Quality Consistency Directness High protein 
intervention 
Standard 
diet/ Placebo 
MD/ SMD / RR (CI) P value I2 
QOL  
(SF-36) 
RCT Low Low Moderate 42 51 SMD -0.10 (-0.51-0.31) 0.62 0% LOW 
QOL  
(EQ-5D) 
RCT Low Low Moderate 53 51 SMD 2.58 (2.05-3.10) <0.00001 N/A LOW 
Adverse effects  
(group total) 
RCT Low Low High 335 268 RR 1.11 (0.70-1.76) 0.67 20% LOW 
Adverse effects  
(>20%/>20g protein) 
RCT Low Low High 82 83 RR 1.28 (0.64-2.55) 0.48 62% LOW 
Deaths 
(group total) 
RCT Moderate Moderate High 167 140 RR 0.53 (0.22-1.25) 0.15 0% LOW 
Deaths 
(>20%/>20g protein) 
RCT Moderate Moderate High 45 42 RR 0.40 (0.11-1.45) 0.16 N/A LOW 
Functional assessment 
(group total) 
RCT Low Low High 115 117 SMD -0.04 (-0.29-0.22) 0.79 0% LOW 
Functional assessment  
(>20%/>20g protein) 
RCT Low Low High 67 72 SMD -0.11 (-0.44-0.23) 0.53 0% LOW 
Change in mean body 
weight (group total) 
RCT High High High 446 440 MD 1.11 (0.97-1.24-) <0.00001 75% MODERATE 
Change in mean body 
weight (>20%/>20g 
protein) 
RCT High Moderate High 50 87 MD 2.12 (1.34-2.91) <0.00001 81% MODERATE 
Change in mean BMI 
(group total) 
RCT High High High 242 228 MD 0.86 (0.61-1.10) <0.00001 0% HIGH 
Change in mean BMI  
(>20%/>20g protein) 
RCT High High High 65 79 MD 1.05 (0.68-1.41) 0.0004 0% HIGH 
Change in mean MAC 
(group total) 
RCT Moderate Low High 163 172 MD 0.51 (0.23-0.79) 0.0004 73% LOW 
Change in mean MAC 
(>20%/>20g protein) 
RCT Moderate Low High 57 70 MD 0.64 (0.11-1.18) 0.02 83% LOW 
Grip strength 
(group total) 
RCT Low Low High 122 128 MD 0.63 (-0.05-1.32) 0.07 60% LOW 
Grip strength RCT Low Low High 77 87 MD -0.63 (-1.80-0.53) 0.29 33% LOW 
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(>20%/>20g protein 
 
 
 
 
Figure S1: PRISMA flow diagram summarising the results of the search strategy 
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Figure S2: Results of the Risk of Bias assessment 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3: Forest plot to compare the assessment of mortality between the interventions on 
meta-analysis. 
 
 
 
 
 
 
 
 
Figure S4: Forest plot to assess the functional assessment scores between the intervention 
groups, on meta-analysis. 
 
 
 
 
 
 
 
 
Figure S5: Forest plot to assess the change in mean body weight on meta-analysis 
 
 
 
 
 
 
 
Figure S6: Forest plot to assess the change in mean body mass index on meta-analysis 
 
 
 
 
 
 
 
Figure S7: Forest plot to assess the change in mean mid-upper-arm circumference (MUAC) on 
meta-analysis 
 
 
 
 
 
 
 
 
Figure S8: Forest plot to assess the outcome of grip strength measurement on meta-analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S1: PRISMA Checklist 
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  TITLE PAGE 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key 
findings; systematic review registration number.  
ABSTRACT 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  INTRO Para 3 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
INTRO Para 3 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number.  
Methods, 
Protocol 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
Methods, 
Eligibility 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
Methods, 
Search 
Strategy 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  Table 1 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in 
the meta-analysis).  
Methods, 
Study 
Identification 
 
 
 
 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
Methods, 
Outcomes 
and Data 
Extraction 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications 
made.  
Methods, 
Outcomes 
and Data 
Extraction 
Risk of bias in individual studies  12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used in any data synthesis.  
Methods, 
Quality 
Assessment 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  Methods, 
Data Analysis 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for 
each meta-analysis.  
Methods, 
Data 
Analysis, 
Para 1 
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Section/topic  # Checklist item  Reported on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within 
studies).  
Methods, 
Data 
Analysis, 
Para 3 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were 
pre-specified.  
Methods, 
Data 
 
 
 
 
Analysis, 
Para 2 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, 
ideally with a flow diagram.  
Supplement 
Figure 1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the 
citations.  
Table 1 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Table 2 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group 
(b) effect estimates and confidence intervals, ideally with a forest plot.  
Results, 
Figure 1,2  
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  Results, 
Figure 1,2 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  Results, 
section 
throughout 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  Results, 
section 
throughout 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups 
(e.g., healthcare providers, users, and policy makers).  
Discussion, 
Para 1 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias).  
Discussion, 
Para 5 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  Discussion 
Para 2-4 
 
 
 
 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
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Table S2: Search strategy for MEDLINE 
PICOS Component Search Strategy 
Population None Applied 
Intervention 1. Nutrit* 
2. exp Nutrition Therapy/ 
3. exp Diet/ 
4. exp Diet Therapy/ 
5. exp Eating/ 
6. Oral nutritional supplement.ti.ab. 
7. exp Dietary Supplements/ 
8. exp Nutritional Support/ 
9. Suppl*.ti.ab. 
10. exp Dietary Proteins/ 
11. (protein*) AND (feed* OR nutrit*) 
Comparison None Applied 
Outcome None Applied  
Setting Design 12. Care home*.ti.ab. 
13. Old age home*.ti.ab. 
14. Exp Homes for the Aged/ 
15. Nursing home.ti.ab. 
16. Residential home.ti.ab. 
17. Residential facilities.ti.ab. 
Design 18. Randomised.ti.ab. 
19. Randomized.ti.ab. 
20. Controlled trials.ti.ab 
21. RCT.ti.ab 
 22. OR/1-11 
23. OR/12-17 
24. OR/18-21 
25. AND/22-24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
